Market Overview

Santarus Pharming, Announce New Data from Open-Label Repeat Treatment Study with RUCONEST


Santarus (NASDAQ: SNTS) and Pharming Group NV (OTC: PHGUF) announced that new data from an open-label extension of the
pivotal Phase III clinical study with RUCONEST® (recombinant
human C1 esterase inhibitor, or rhC1INH) will be featured in a poster
presentation on November 9 & 10, 2013 at the 2013 American College of
Allergy, Asthma & Immunology Annual Scientific Meeting at the Convention
Center in Baltimore, Maryland. The poster is titled, Efficacy and
Safety of Recombinant Human C1 Esterase Inhibitor for Acute Attacks of
Hereditary Angioedema: An Open-Label Study.

RUCONEST was administered for the treatment of 224 repeat acute
angioedema attacks in 44 patients with hereditary angioedema (HAE)
following initial treatment

See full press release

Posted-In: News Guidance Offerings Contracts Asset Sales FDA Management Global


Related Articles (SNTS + PHGUF)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Proteo Announces Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed

TransGlobe Energy Signs New Concession Agreements in Egypt